A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection
Alzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of nerve cells, which leads to impairment of various cognitive functions. A significant biomarker of Al...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Sensors |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsens.2024.1508810/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065340105490432 |
|---|---|
| author | Claudia do Amaral Razzino Claudia do Amaral Razzino Lívia Flório Sgobbi Juliana Cancino-Bernardi Angelica Maria Mazuera Zapata Clara Cardoso Costa Valtencir Zucolotto Lucia Vieira Anderson Oliveira Lobo |
| author_facet | Claudia do Amaral Razzino Claudia do Amaral Razzino Lívia Flório Sgobbi Juliana Cancino-Bernardi Angelica Maria Mazuera Zapata Clara Cardoso Costa Valtencir Zucolotto Lucia Vieira Anderson Oliveira Lobo |
| author_sort | Claudia do Amaral Razzino |
| collection | DOAJ |
| description | Alzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of nerve cells, which leads to impairment of various cognitive functions. A significant biomarker of Alzheimer’s disease is the decreased level of soluble β-amyloid peptide (1–42) (Aβ1-42) in cerebrospinal fluid (CSF), as pathology progresses when CSF-Aβ1-42 levels drop below 192 pg mL−1. In this study, we developed an amperometric immunosensor based on magnetic beads as the platform for constructing the immunosensor. Monoclonal antibodies are immobilized on the MBs, enabling selective detection of Aβ1-42. The detection antibody is conjugated with the enzyme horseradish peroxidase, which, in the presence of H2O2 and hydroquinone, catalyzes the decomposition of H2O2 and the oxidation of hydroquinone to p-quinone, generating an electric current measured at a potential of −200 mV (vs. the Ag pseudo-reference electrode) using screen-printed carbon electrodes. The amperometric sandwich-type immunosensor demonstrates a linear response in the concentration range of 10 to 10,000 pg mL−1, with a detection limit of 7.4 pg mL−1, exhibiting excellent selectivity against the assessed interferents. These findings suggest the potential application of this immunosensor in the early diagnosis of Alzheimer’s disease, offering a sensitive and specific tool for clinical analysis. Despite its high performance, further studies are required to validate its robustness and applicability in complex clinical samples. |
| format | Article |
| id | doaj-art-10496aea2ffd4f54ab271536c89d6c29 |
| institution | DOAJ |
| issn | 2673-5067 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Sensors |
| spelling | doaj-art-10496aea2ffd4f54ab271536c89d6c292025-08-20T02:49:02ZengFrontiers Media S.A.Frontiers in Sensors2673-50672024-12-01510.3389/fsens.2024.15088101508810A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detectionClaudia do Amaral Razzino0Claudia do Amaral Razzino1Lívia Flório Sgobbi2Juliana Cancino-Bernardi3Angelica Maria Mazuera Zapata4Clara Cardoso Costa5Valtencir Zucolotto6Lucia Vieira7Anderson Oliveira Lobo8Research and Development Institute, University of Vale do Paraiba, São José dos Campos, BrazilNanomedicine and Nanotoxicology Group, Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, BrazilInstitute of Chemistry, Federal University of Goias, Goiania, BrazilDepartment of Chemistry, Faculty of Philosophy, Sciences and Letters of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, BrazilNanomedicine and Nanotoxicology Group, Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, BrazilDepartment of Chemistry, Faculty of Philosophy, Sciences and Letters of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, BrazilNanomedicine and Nanotoxicology Group, Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, BrazilResearch and Development Institute, University of Vale do Paraiba, São José dos Campos, BrazilInterdisciplinary Laboratory for Advanced Materials, Federal University of Piaui, Teresina, BrazilAlzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of nerve cells, which leads to impairment of various cognitive functions. A significant biomarker of Alzheimer’s disease is the decreased level of soluble β-amyloid peptide (1–42) (Aβ1-42) in cerebrospinal fluid (CSF), as pathology progresses when CSF-Aβ1-42 levels drop below 192 pg mL−1. In this study, we developed an amperometric immunosensor based on magnetic beads as the platform for constructing the immunosensor. Monoclonal antibodies are immobilized on the MBs, enabling selective detection of Aβ1-42. The detection antibody is conjugated with the enzyme horseradish peroxidase, which, in the presence of H2O2 and hydroquinone, catalyzes the decomposition of H2O2 and the oxidation of hydroquinone to p-quinone, generating an electric current measured at a potential of −200 mV (vs. the Ag pseudo-reference electrode) using screen-printed carbon electrodes. The amperometric sandwich-type immunosensor demonstrates a linear response in the concentration range of 10 to 10,000 pg mL−1, with a detection limit of 7.4 pg mL−1, exhibiting excellent selectivity against the assessed interferents. These findings suggest the potential application of this immunosensor in the early diagnosis of Alzheimer’s disease, offering a sensitive and specific tool for clinical analysis. Despite its high performance, further studies are required to validate its robustness and applicability in complex clinical samples.https://www.frontiersin.org/articles/10.3389/fsens.2024.1508810/fullscreen-printed electrodemagnetic beadsamperometric immunosensoramperometric sandwich immunoassayβ-amyloid peptide (1–42) |
| spellingShingle | Claudia do Amaral Razzino Claudia do Amaral Razzino Lívia Flório Sgobbi Juliana Cancino-Bernardi Angelica Maria Mazuera Zapata Clara Cardoso Costa Valtencir Zucolotto Lucia Vieira Anderson Oliveira Lobo A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection Frontiers in Sensors screen-printed electrode magnetic beads amperometric immunosensor amperometric sandwich immunoassay β-amyloid peptide (1–42) |
| title | A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
| title_full | A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
| title_fullStr | A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
| title_full_unstemmed | A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
| title_short | A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
| title_sort | microbead enhanced electrochemical platform for β amyloid peptide 1 42 detection |
| topic | screen-printed electrode magnetic beads amperometric immunosensor amperometric sandwich immunoassay β-amyloid peptide (1–42) |
| url | https://www.frontiersin.org/articles/10.3389/fsens.2024.1508810/full |
| work_keys_str_mv | AT claudiadoamaralrazzino amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT claudiadoamaralrazzino amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT liviafloriosgobbi amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT julianacancinobernardi amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT angelicamariamazuerazapata amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT claracardosocosta amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT valtencirzucolotto amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT luciavieira amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT andersonoliveiralobo amicrobeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT claudiadoamaralrazzino microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT claudiadoamaralrazzino microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT liviafloriosgobbi microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT julianacancinobernardi microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT angelicamariamazuerazapata microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT claracardosocosta microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT valtencirzucolotto microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT luciavieira microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection AT andersonoliveiralobo microbeadenhancedelectrochemicalplatformforbamyloidpeptide142detection |